New drug interaction study aims to keep sickle cell patients safe
NCT ID NCT06813924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study in 37 healthy adults tested whether a new drug called etavopivat affects how the body processes five common medicines: digoxin, rosuvastatin, midazolam, pitavastatin, and metformin. Participants took etavopivat daily for 10 days along with single doses of each other drug. The goal was to see if etavopivat changes the levels of these medicines in the blood, which could help guide safe dosing for future patients with sickle cell disease or thalassemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etavopivat
- What this could lead to
- If successful, this study could help doctors understand how to safely combine etavopivat with other common medicines in future treatments for sickle cell disease or thalassemia.
- What could go wrong
- This is an early-stage study in healthy volunteers, not patients. Results may not fully predict how the drug interacts in people with the actual diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS SICKLE CELL DISEASE, THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON-Salt Lake City
Salt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.